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Background: Transcutaneous vaccines have received wide attention due to their easy-to-use, 
needle-free, noninvasive delivery. However, the novel barrier function of stratum corneum 
hinders the transport of antigen and adjuvant in transcutaneous immunization. Novel nanoscale 
delivery systems employing, for example, liposomes and nanoparticles, have been widely 
investigated to overcome the penetration barrier of stratum corneum for effective transcutane-
ous immunization.
Objective: The objective of this study was to prepare two types of flexible liposomes and 
determine their efficacies for the transcutaneous delivery of antigen and the subsequent immune 
response induced in vivo.
Methods: Ovalbumin (OVA) liposome-based transcutaneous vaccines were prepared using 
reverse-phase evaporation and film-dispersion methods. Particle sizes and antigen encapsulating 
efficiency were then evaluated. After application to bare mouse skin, topical sites were exam-
ined for the presence of fluorescence-labeled liposome. The efficacy of the transcutaneously 
delivered OVA-loaded flexible liposome in activating the immune responses was investigated 
by detecting serum immunoglobulin G levels. The influence of an adjuvant, imiquimod, in the 
transcutaneous immunization was also tested.
Results: Two flexible liposomes with well-encapsulated OVA were successfully prepared by 
film-dispersion or reverse-phase evaporation methods. The sizes of the prepared flexible lipo-
somes ranged from 200 to 400 nm. In vivo, the fluorescence-labeled liposome was detected in 
hair-follicle ducts, indicating that the flexible liposome can penetrate the skin barrier through 
the hair follicles. Upon transcutaneous administration, the OVA-encapsulated flexible lipo-
some elicited a strong immune response similar to that of positive control (ie, OVA solution 
administrated by subcutaneous injection with Al(OH)3 as an adjuvant). Co-administration of 
imiquimod with the OVA-loaded liposome expressed a significant enhancement on the trans-
cutaneous immune responses.
Conclusion: Results of this study highlight the nanoscale formulation, flexible liposome, as 
a promising carrier for the transcutaneous delivery of antigen proteins. Imiquimod was shown 
to be an effective adjuvant as a transcutaneous immunization enhancer with the potential for 
transcutaneous vaccine development.
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Introduction
As a biological preparation that improves immunity to a particular disease, vaccine 
is one of the most important accomplishments in medicine. Vaccines based on active 
peptides and proteins have been developed as a consequence of the progress of bio-
technological techniques and genetic engineering. However, while most   vaccines International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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administered via injection are effective, the problems of 
pain, needle-related infections or injuries, the need for 
trained personnel, and storage or transport issues remain.1 
The practice of reusing needles causes the death of at least 
1.3 million people per year from hepatitis B and acquired 
immune deficiency syndrome, therefore the desire to elimi-
nate hypodermic needles greatly motivates the development 
of needle-free vaccines.2 Transcutaneous immunization is a 
new method that utilizes topical application of an adjuvant 
and vaccine antigen to intact skin for vaccination.3 In this 
strategy, antigen with novel formulations is delivered by 
transporting the antigen to the epidermis. The antigen is then 
taken up by Langerhans cells and migrates to lymph nodes4 
to induce an immune response. Transcutaneous immuniza-
tion by topical drug-delivery systems incorporating antigens 
avoids direct contact between potent adjuvants (sometimes 
slightly toxic) and the general circulation, hence offering 
the advantages of rapid distribution, self-administration, 
and enhanced safety.5,6 Due to its easy-to-use, needle-free, 
and noninvasive features, transcutaneous immunization 
represents an attractive alternative to vaccine delivery via 
subcutaneous and intramuscular routes.7
For example, the authors have recently reported a 
hydrogel patch formulation that was shown to promote the 
penetration of antigenic proteins into stratum corneum to 
induce a strong immune response.8,9 However, transcutane-
ous vaccine has not been exploited to its full potential due 
to the inherent barrier function of stratum corneum. As it is 
not easy for large proteins and viral particles to penetrate 
through stratum corneum under natural conditions, the main 
challenge for transcutaneous immunization is thus to enhance 
the crossover of antigens through the epidermis and initiate 
physical effective immunogenicity. Currently, in addition to 
disrupting the skin barrier by removal of stratum corneum, 
increasing efforts have been put into developing nanometer 
drug-delivery systems. For example, nanoparticles and trans-
fersomes achieve transcutaneous immunization enhancement 
by stimulating skin penetration and protecting the antigen 
from degradation, which enables uptake by more antigen-
presenting cells (APCs). In the authors’ previous studies, 
nanoscaled transfersomes10–13 and nanoparticles14–17 have been 
shown to be excellent carriers capable of delivering antigenic 
proteins to APCs. They elicit potent immune responses based 
on antigen-specific cytotoxic T lymphocytes and promote the 
migration of the antigen-capturing APCs to regional lymph 
nodes via subcutaneous injection or nasal cavity. Among 
them, the novel vesicular carrier system known as transfer-
somes, composed of phospholipid, surfactant, and water, 
proved to be effective for transdermal delivery enhancement. 
With a similar structure to biological membranes, the trans-
fersomal system, which includes deformable liposomes and 
noisomes, have been formulated for the topical/transdermal 
delivery of bioactive compounds, for example, antibiotics, 
proteins, and nucleic acids for skin penetration. The fre-
quency of using transcutaneous protein delivery by means 
of transfersomes is reported to be increasing.18 Methods have 
been used for the encapsulation of peptides and proteins in 
liposomes. Currently, several methods have been developed 
to form unilamellar vesicles from multibilayers,19 for exam-
ple, the film-dispersion,20 reverse-phase evaporation,21 and 
dehydration-rehydration methods.22 Furthermore, to increase 
liposome flexibility, ethanol and the nonionic surfactant 
polysorbate 80 could be incorporated for the preparation of 
flexible liposomes (FLs), which contain phosphatidylcholine 
and a surfactant, and consists of at least one inner aqueous 
compartment surrounded by a lipid bilayer. When mixed with 
stratum corneum lipids, FLs can carry a remarkable amount 
of lipid mass into the skin and therefore be advantageous in 
promoting the cutaneous drug disposition after disrupting the 
skin barrier with its flexible bilayer.23 It has been reported 
that FLs could stimulate transcutaneous immune response 
by acting as an adjuvant.24 Furthermore, besides the physical 
and pharmaceutical methods, adjuvants are frequently used 
in immunology to stimulate the immune system to increase 
the response to a vaccine. The combination of adjuvant and 
specific vaccine antigen can accelerate, prolong, or enhance 
antigen-specific immune responses. The range of adjuvant 
candidates is wide. The colloidal aluminum hydroxide and 
Freund’s adjuvant are commonly used candidates. However, 
not all of these adjuvants are effective in the transcutaneous 
immunization due to their relatively large sizes, which do 
not favor skin penetration. In this study, a fluorescent mate-
rial, fluorescein sodium (NaFl), was chosen to prepare FLs 
along with a suitable amount of sodium deoxycholate as a 
surfactant. It was found that this FL could enhance drug 
content in the skin. Secondly, the ratio of phospholipids S 
100 and cholesterol, types of organic solvent, and the amount 
of ovalbumin (OVA) were optimized when the drug was 
changed from NaFl to OVA. The optimizations were achieved 
by characterization of particle size, entrapment efficiency, 
and stability. FLs were first prepared with the optimized 
film-dispersion and reversed-phase evaporation methods and 
characterized in vitro. The entrapment efficiency and release 
properties of the FLs for a model antigen, OVA, were then 
evaluated. Later, transcutaneous OVA delivery, transferred 
by the FLs, was studied before the investigation of in vivo International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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transcutaneous immunization. Additionally, several other 
immunogenic adjuvants were evaluated for their applications 
in transcutaneous immunization and their influence on the 
efficacy of OVA-FLs vaccine.
Materials and methods
Materials
Phospholipid S 100 was obtained from Avanti Polar   Lipids 
(Alabaster, AL). OVA and cholesterol were obtained from 
Sigma-Aldrich (St Louis, MO). Sephadex G-100 was obtained 
from Beijing Henghui Science and Technology Development 
(Beijing, China). NaFl, Tween® 20, and sodium deoxycholate 
were from Aladdin (Shanghai, China) and Imiquimod was 
from Dinghui Chemical (Wuhan, China). BCA kit was from 
Nanjing BiYunTian kits biotechnology company (Jiangsu, 
China). Horseradish peroxidase conjugated goat antimouse 
IgG was obtained from Wuhan Boster (Wuhan, China). 
Fluorescein isothiocyanate-conjugated OVA was acquired 
from Beijing Boaosen biotechnology (Beijing, China). All 
reagents were of analytic grade and used as received without 
further purification.
Instruments
Malvern Zetasizer (Zeta Master; Malvern Instruments Ltd, 
Malvern, UK) and a microplate enzyme-linked immuno-
sorbent assay reader KHB ST-360 (an automatic microplate 
reader, Shanghai Zhihua Medical Instrument, China).
Methods
Preparation of common liposomes  
(CLs) by film-dispersion method
To prepare CLs using this method, 200 mg phospholipids 
S 100 and 50 mg cholesterol were dissolved in 15 mL chlo-
roform, dried under reduced pressure in a round-bottom 
glass flask and stored in vacuum for at least 1 hour, in order 
to make a very thin film. The lipid film was then hydrated 
with 5 mL of distilled water using 8 mg NaFl. Later, 5 mL 
phosphate-buffered saline (PBS) solution was added. After 
hydration of the film, large vesicles arose, entrapping solvent 
and solutes in their aqueous core and between lamellae. The 
suspensions were vortexed gently for 2–3 hours, followed 
by sonication for 30 minutes.
Preparation of cLs by reverse-phase 
evaporation method
With the reverse-phase evaporation dispersion method, 200 mg 
phospholipids S 100 and 50 mg cholesterol were dissolved in 
15 mL chloroform. Later, 8 mg NaFl diluted in 5 mL distilled 
water was added. Using probe sonication (400 W, 2 minutes), 
the w/o emulsions were formed and dried under reduced pres-
sure for 15 minutes in a round-bottom glass flask. After solvent 
evaporation, the compartments were collapsed to give a gel, 
5 mL PBS solution was added, and the suspensions were gently 
vortexed under vacuum for at least 3 hours.
Preparation of FLs by film-dispersion 
method
FLs were prepared in this way by dissolving 200 mg phos-
pholipids S 100 and 50 mg cholesterol in 15 mL chloroform. 
This was dried under reduced pressure in a round-bottom 
glass flask and stored in vacuum for at least 1 hour to make 
a very thin film. The lipid film was then hydrated with 5 mL 
of distilled water with 25 mg OVA (A5503; Sigma-Aldrich). 
Later, 30 mg sodium deoxycholate diluted in 5 mL PBS solu-
tion was added. Large vesicles formed after hydration of the 
film, entrapping solvent and solutes in their aqueous core and 
between lamellae. The suspensions were vortexed gently for 
2–3 hours followed by sonication for 30 minutes.
Preparation of FLs by reverse-phase 
evaporation method
With the reverse-phase evaporation dispersion method, 
200 mg phospholipids S 100 and 50 mg cholesterol were dis-
solved in 15 mL chloroform. After this, 25 mg OVA diluted 
in 5 mL distilled water was added. Using probe sonication 
(400 W, 2 minutes), the w/o emulsions formed were dried 
under reduced pressure for 15 minutes in a round-bottom 
glass flask. After solvent evaporation, the compartments were 
collapsed to give rise to a gel, 30 mg sodium deoxycholate 
diluted in 5 mL PBS solution was added, and the suspensions 
were gently vortexed under vacuum for at least 3 hours.
In vitro diffusion studies of different  
NaFl formulations
To determine the distribution of different NaFl formulations 
in the stratum corneum and viable skin, in vitro diffusion 
studies were carried out. The pig skin used was prepared from 
full thickness tissue, which had been cleaned of underlying fat 
then mounted in Franz-type diffusion cells with an exposed 
surface area of approximately 2.83 cm2 and receptor phase 
volume of roughly 6.8 mL saline. One milliliter of each 
prepared NaFl formulation was added in the supply phase. 
The receptor phase was continuously stirred with magnetic 
fleas and maintained in a water bath at 37°C to give a skin International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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surface temperature of ∼32°C. The NaFl formulations were 
divided into the following groups:
•	 Solution: NaFl solution
•	   CLs (reverse): CLs prepared by reverse-phase   evaporation 
method
•	 CLs (film): CLs prepared by film-dispersion method
•	   FLs (reverse): FLs prepared by reverse-phase evaporation 
method
•	 FLs (film): FLs prepared by film-dispersion method.
After 8 hours, the skins were washed with saline. The 
distribution of NaFl in the skin was directly assessed using 
adhesive tape (ScotchTM; 3M Co, Two Harbors, MN), using 
the tape-stripping method. Tape stripping was performed 
30 times on the surface of the skin. Each strip was removed 
with one quick movement. The stripped tapes (NaFl in stratum 
corneum) were put in a beaker and the NaFl was separated 
from the tape using 10% isopropanol diluted in saline. Any 
residual NaFl left in the viable skin after tape stripping was 
also extracted. The viable skin was cut into pieces, diluted in 
5 mL saline mixture, sonicated for 1 hour, and centrifuged to 
extract the supernatant. Saline (5 mL) was added to the pellet 
after centrifugation, and then ultrasound and centrifuged to 
extract the supernatant; the two supernatants were combined 
together for determination. The NaFl content in the stratum 
corneum and viable skin were determined by fluorescence 
spectrophotometer.
characterization of OVA-FLs
The structure and surface characteristics of the prepared 
liposome systems were viewed under transmission electron 
microscope (JEM-1230; JEOL, Tokyo, Japan). A drop of 
liposome dispersion was diluted with deionized water. A drop 
of the diluted liposome dispersion was then applied onto a car-
bon coated 300 mesh copper grid and left for 1 minute to allow 
the adherence between liposome and the carbon   substrate. 
Excess of dispersion was removed by blotting the drop with 
filter paper. Using 1% w/v phosphotungstic acid solution 
for negative staining, the grid was kept in phosphotungstic 
acid solution for 2 minutes and observed under transmission 
electron microscope under wet conditions. Photographs 
were taken to reveal morphological details of vesicular   
assemblages. The FLs were also characterized for their sizes, 
PDI, and zeta potential with a dynamic light-  scattering method, 
in a multimodal mode using a computerized inspection sys-
tem (Zeta Master; Malvern Instruments Ltd, Malvern, UK). 
For size measurement of vesicles, vesicular suspension was 
mixed with the appropriate medium (PBS pH 6.5) and mea-
surements were conducted in triplicate.
Antigen entrapment efficiency of FLs
Entrapment efficiency of the OVA in FLs was determined after 
separating free OVA from the liposomes by molecular exclu-
sion chromatography using a Sephadex G-100 minicolumn. 
Briefly, OVA-loaded liposomes were suspended in 5 mL 
water and put into a space of Sephadex G-100 minicolumn 
centrifugation, which was spun to separate the free OVA 
from liposome dispersions. The unentrapped antigen was 
removed after centrifugation, together with the Sephadex 
G-100 minicolumn. Free OVA medium (20µL) was taken 
for OVA measurement by standardized bicinchoninic acid 
(BCA) measurement method. Entrapment efficiency was 
defined as the ratio of liposome-associated OVA to total OVA 
used. The experiments were performed in triplicate.
OVA stability in FLs
For the characterization of antigen bioactivity, the integrity of 
OVA under nondenaturing condition was identified through 
sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) under reducing conditions. OVA was identi-
fied through SDS-PAGE under reducing conditions using 
a known concentration of OVA in 5% stacking gel and 
15% separation (resolving) gel (Bio-Rad Laboratories, Inc, 
Richmond, CA). Protein bands were detected by Coomassie 
Brilliant Blue staining. In the presence of the strong reduc-
ing agent sodium dodecyl sulfate (SDS) and heat, the pro-
teins were dissociated before they were applied on the gel. 
  SDS-PAGE experiments were performed on 5% stacking gel 
and 8% resolving gel following the standardized protocol. The 
samples were heated to 95°C for 5 minutes prior to running. 
After electrophoresis, the gel with samples was dried.
In vitro release of OVA from FLs
Briefly, 5 mL of the OVA-loaded liposome dispersions 
after the Sephadex G-100 minicolumn centrifugation was 
transferred into a large tube containing 30 mL phosphate 
buffer (pH 7.4) in thermostat oscillators at 37°C ± 1°C and 
mechanically shaken at a suitable rotation speed. At designated 
time intervals, 0.5 mL sample of the dialysis medium was 
taken for BCA protein measurement of OVA and the same 
volume of fresh medium was then added. The above 0.5 ml 
samples were centrifuged at a speed of 20,000 rpm to separate 
the released OVA (supernatant) and the intact liposome 
dispersions (pellet). The concentration of supernatant was 
measured for the released OVA using a BCA kit. The protocol 
of the BCA kit is similar to the aforementioned method used 
to determine the antigen entrapment efficiency of FLs. The 
release experiments were performed in triplicate.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Transcutaneous delivery of OVA-FLs  
in vivo
Female BALB/c mice 6–8 weeks old (18–20 g) were used 
in all experiments. All animal experiments were conducted 
in accordance with the national regulations for care and 
use of laboratory animals. Mice were anesthetized with 
pentobarbital sodium. Most of the hair from the abdominal 
part of each mouse was shaved. Neither cut nor skin 
irritation was observed. The shaved area was wiped with 
cotton swab. Liposome formulations loaded with fluorescein 
isothiocyanate-conjugated OVA (FITC-OVA) were uniformly 
applied onto the shaved area (2 × 2 cm), using a pipette tip, for 
30 minutes. Mice were then sacrificed and their backs were 
washed twice with water and dried with a cotton swab. Skin 
samples of 1 × 1 cm from the treated areas were removed and 
frozen. Sections 6 µm thick were obtained using a Leica CM 
1500 (Leica Biosystems GmbH, Wetzlar, Germany) cryotome 
and collected on a glass slide. Fluorescence microscopy 
was used for detection. The fluorescent liposomes produced 
green signals.
Transcutaneous immunization  
of OVA-FLs in vivo
Groups of seven mice were immunized by topical applica-
tion of different OVA formulations (each containing 200 µg 
OVA). Mice were shaved and various antigen formulations 
were applied as described. After 1 hour, the shaved area 
was washed with water and dried with a cotton swab. Imi-
quimod (5 µg/mouse) was included in certain formulations 
as adjuvant. An equal booster dose of each formulation was 
administered by the same route fortnightly. The following 
groups were included in the study:
•	 Group 1: liposome 1 (prepared by film-dispersion method) 
with or without adjuvant imiquimod by transcutaneous 
immunization.
•	 Group 2: liposome 1 (prepared by film-dispersion method) 
applied on intact skin or pretreated skin where stratum 
corneum was removed transcutaneously; imiquimod was 
applied as an adjuvant.
•	 Group 3: liposome 1 (prepared by film-dispersion method) or 
liposome 2 (prepared by reverse-phase evaporation method) 
applied on pretreated skin with stratum corneum removed 
transcutaneously; imiquimod was applied as an adjuvant.
•	 Group 4: liposome 1 (prepared by film-dispersion 
method) applied transcutaneously on intact skin, with 
the adjuvant imiquimod; positive control mice were 
subcutaneously injected with 200 µg OVA solution with 
Al(OH)3 as adjuvant.
Blood samples were collected fortnightly (2, 4, 6, and 
8 weeks) after primary immunization.
Determination of specific anti-OVA 
immunoglobulin (Ig) g antibody 
levels in the serum by enzyme-linked 
immunosorbent assay
One hundred microliters of OVA (10 µg/mL in phosphate 
buffer, pH 7.4) was used to coat each well of a 96-well plate, 
which was then incubated at 4°C overnight. Following this, 
the plate was washed three times with TTBS (0.05% [v/v] 
Tween® 20 in tris-buffered saline) to remove unloaded OVA. 
Fifty microliters of 5% bovine serum albumin was added 
into each well and plate was incubated for 2h at room tem-
perature and washed three times with TTBS. One hundred 
microliters of diluted serum sample was added to each well 
and incubated for another 2 hours at room temperature and 
later washed three times with TTBS. One hundred microliters 
of diluted horseradish peroxidase conjugated goat antimouse 
IgG was added to each well and incubated for 2 hours. The 
plate was washed again three times with TTBS and then 
100 µL of substrate solution (3,3,5,5-tetramethyl benzidine 
containing hydrogen peroxide) was added to each well. The 
plate was then incubated in darkness at room temperature 
for 15 minutes. Adding 50 µL of 2 M H2SO4 to each well 
terminated the reaction. The absorbance was measured at 
450 nm using a microplate enzyme-linked immunosorbent 
assay reader (Lab System Multiscan, Finland).
Statistical analysis
Data were expressed as mean and standard deviation (SD). 
Statistical significance of the differences between groups was 
assessed using Student’s t-test. Analysis of variance was used 
for comparison of more than two samples. Difference of two-
tailed P , 0.05 was considered statistically significant.
Results
Preparation and characterization  
of the liposome formulations
In previous work, the authors chose the fluorescent water-
soluble material NaFl to prepare two types of FLs (data not 
shown). Determination of NaFl in the skin by transcutaneous 
delivery revealed that, compared with both the CL and the 
NaFl solution groups, NaFl contents in the stratum corneum 
and viable skin were significantly increased in the FL groups 
(Table 1). In addition, the two FLs with well-encapsulated 
OVA, either by film-dispersion or reverse-phase evaporation 
methods, were successfully prepared. The properties of the International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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two liposomes were characterized via vesicle size and size 
distribution with a Malvern Zetasizer (Figure 1A). Their 
structure and surface characteristics were measured using 
a transmission electron microscope (Figure 1B).   According 
to the transmission electron microscope images, the dis-
crete liposomes 1 and 2 were spherical and their round 
shapes would be maintained with homogeneous structures. 
The liposomes were measured at 200–400 nm. With BCA 
protein assays, the OVA entrapment efficiency of liposome 
1 and liposome 2 were determined as 47.9% ± 8.9% and 
77.9% ± 19.2%, respectively.
OVA stability in FLs
As a major protein of chicken egg white, OVA has an appar-
ent molecular weight of 40, 45, 63, and 72 kDa. Both giant 
molecules (high molecular weight products) that could not 
enter the large-pore spacer gel and small molecules from 
OVA were observed by SDS-PAGE. In SDS-PAGE under 
nonreducing conditions, the OVA is visualized as the two 
distinctive bands 40 kDa and 45 kDa. These are the specific 
bands for the identification of OVA protein, the molecular 
weight of which is approximately 43 kDa. This indicated 
OVA was encapsulated well in liposomes, and was kept 
active and stable in the formulations (Figure 1D).
In vitro release of OVA from FLs
The in vitro release profiles of OVA from the two types of FLs 
were also determined. It was found that .85% OVA loaded 
onto liposome 1 was detected in the release medium within 
1 hour, whereas OVA incorporated in liposome 2 showed 
a slower release profile with OVA contents in the release 
medium reaching 85% after 5 hours (Figure 2).
Transcutaneous delivery of OVA-FLs  
in vivo
In Figure 3, it can be seen that in the skin samples in which 
fluorescent liposomes were applied, intense fluorescence from 
the FITC label (green) could be observed with the green fluo-
rescence detector. The liposome formulation immersed with 
FITC-OVA solution formed a concentrated antigen layer on its 
surface, an FITC label on the surface of the skin as well as along 
the hair follicle (Figure 3Bii), and sweat glands (Figure 3Cii) 
Table 1 Distribution of different NaFl formulations in the stratum corneum and viable skin
Distribution Solution CLs (reverse) CLs (film) FLs (reverse) FLs (film)
stratum corneum   7.62 ± 1.84   22.92 ± 0.87**   17.53 ± 4.53*   16.83 ± 3.15*   8.81 ± 5.43
Viable skin 991.57 ± 43.67 1980.92 ± 661.19 628.03 ± 27.62* 2894.59 ± 178.79** 930.46 ± 356.25
Notes: All the formulations were applied by transcutaneous route in the pig skin (ng/cm2, mean ± sD, n = 3). The statistical significance of the differences between groups 
was investigated using student’s t-test. *Versus solution group, P , 0.05; **versus solution group, P , 0.01. solution: NaFl solution.
Abbreviations: CLs (reverse), common liposomes prepared by reverse-phase evaporation method; CLs (film), common liposomes prepared by film-dispersion method; 
FLs (reverse), flexible liposomes prepared by reverse-phase evaporation method; FLs (film), flexible liposomes prepared by film-dispersion method; NaFl, fluorescein 
sodium.
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inside the skin could clearly be observed. Intense fluorescence 
was observed at the skin mesenchymal and (hair) follicle sites 
after topical application of the FITC-OVA-loaded liposomes 
onto the skin. It is postulated that hair follicles are the major 
route for crossover of liposome 1. In contrast, sweat glands 
were the main channel for liposome 2 to pass through.
Transcutaneous immunization  
of OVA-FLs in vivo
Here, the in vivo efficiency of OVA-loaded liposomes in 
activating the transcutaneous immunization after topical 
application was investigated. Both FLs elicited high immune 
response, while liposome 1 seemed to possess a stronger 
efficiency in producing titer than liposome 2. The film-
dispersion method is superior for the liposome preparation 
for application in transcutaneous immunization (Figure 4C); 
therefore, liposome 1 was selected for the following in vivo 
study. In this study, imiquimod was tested for its efficiency 
in transcutaneous immunization enhancement. As can be 
seen in Figure 4A, compared with OVA-loaded liposome 
alone, OVA-loaded liposomes in combination with imi-
quimod achieved significantly higher levels of anti-OVA 
IgG (P , 0.05) at week 8. In another preliminary study, the 
removal of stratum corneum was found to enhance the anti-
OVA IgG levels elicited by OVA solution, so the authors 
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further investigated whether the disruption of skin barrier 
would increase the transcutaneous immunization efficiency 
of the OVA-loaded liposome (data not shown). However, 
from Figure 4B, it can been seen that there was no significant 
difference between the anti-OVA IgG levels of the intact skin 
group and the stratum corneum pretreated group. Besides, 
the efficiency of both liposome 1 and liposome 2 was tested 
on the stratum corneum pretreated skin, and liposome 
1   represented a significantly higher titer at the 6-week time 
point (Figure 4C). Based on the above results, the transcu-
taneous immunization effect of the OVA-loaded liposome 1 
without any pretreatment of the skin was investigated. In brief, 
the BALB/c mice were vaccinated by either the application 
of nonimmune group (blank control) or liposome 1 applied 
onto the abdominal skin and the injection of OVA solution 
subcutaneously (positive control). The serum anti-OVA IgG 
antibody levels were then determined. By applying FL 1 on 
intact skin, with imiquimod as an adjuvant, strong transcu-
taneous immunizations were achieved (Figure 4D).
Discussion
Nanoscopic therapeutic systems that incorporate biomacro-
molecules, such as protein and peptides, are emerging as the 
next generation of nanomedicine, aiming to improve thera-
peutic efficacy of biomacromolecular drugs. The delivery of 
peptides and proteins intended for therapeutic purposes poses 
unique difficulties in their encapsulation, especially because 
most of them possess a significant hydrophobic component 
and thus show a slow tendency to adsorb onto surfaces. Such 
adsorptive behavior can lead to distinct losses in the amount 
of macromolecule available for delivery.25 Furthermore, 
the amount of peptide or protein to be incorporated within the 
system is dependent on the physicochemical properties of the 
peptide/protein and the production procedures.26 The design 
of novel formulations, especially lipid-based nanoscale car-
riers, seems promising for the disruption of stratum corneum 
through the nano-bio interaction of colloidal carrier with skin 
lipids, protection of proteins and peptides from the external 
environment, and maintenance of long-term activity. These 
properties are conducive to the application of transcutaneous 
vaccines. Transcutaneous immunization by the application of 
a simple vehicle containing antigen and adjuvant appears to 
be a realistic objective. However, the development of novel 
nanoscale systems for transcutaneous immunization is still 
limited by the low efficiency in eliciting robust immune 
response. Apart from the physical techniques to destroy the 
stratum corneum barrier, ultradeformable nanocarriers also 
evoke considerable interest in transcutaneous immunization, 
which may overcome the skin permeability hindrance and 
deliver the antigen to the immunologically active cells of 
skin and draining lymph nodes to raise immune response. 
Liposomes represent a promising carrier system for delivery 
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Figure 4 Anti-OVA Igg responses obtained with liposome formulations by transcutaneous immunization. (A) Liposome 1 (prepared by film-dispersion method) with 
or without adjuvant imiquimod transcutaneously. (B) Liposome 1 (prepared by film-dispersion method) applied on intact skin or stratum corneum pretreated skin 
transcutaneously, imiquimod as an adjuvant. (C) liposome 1 (prepared by film-dispersion method) and liposome 2 applied transcutaneously stratum corneum pretreated 
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Notes: Bars indicate standard deviation (n = 3). Statistical significance was evaluated by one-way ANOVA (*P , 0.05).
Abbreviations: OVA, ovalbumin; Igg, immunoglobulin g; ANOVA, analysis of variance.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3249
Transcutaneous immunization by antigen-loaded flexible liposome
of drugs and biologically active molecules. The lipid-based 
vesicles of liposomes, especially elastic liposomes, may 
change the bioactive permeation kinetics due to an impaired 
barrier function of the stratum corneum, which is helpful for 
skin penetration. FL generally contains phosphatidylcholine 
and a surfactant, and consists of at least one inner aqueous 
compartment surrounded by a lipid bilayer, which can carry 
a remarkable amount of the applied lipid mass into the skin. 
Its flexible bilayer can mix with stratum corneum lipids, 
enhance the drug disposition in skin, and disorder the barrier 
function.24,27,28 In our study, the flexibility of the drug-loaded 
liposome in enhanced skin distribution was demonstrated in 
comparison with CLs and solution (Table 1).
In this study, using optimized reverse-phase evaporation 
and film-dispersion methods, FLs with well-encapsulated 
OVA were prepared. SDS-PAGE results demonstrated that the 
OVA incorporated in the FLs were kept bioactive.29,30 The in 
vitro release profiles indicated that OVA were mainly released 
from the FLs within 1–5 hours. Penetration mechanism study 
demonstrated that the OVA-FLs could gain access into the 
skin through the gap of skin appendages, for example, hair 
follicles and sweat glands. The transcutaneous immune 
responses induced in mice upon the application of OVA 
loaded FL were also examined. However, the large sizes 
of proteins and viral particles makes it difficult for them to 
penetrate through the stratum corneum, so striping the stra-
tum corneum out of the skin to facilitate the skin penetration 
of proteins is therefore a strategy widely investigated for 
transcutaneous immunization enhancement. The penetration 
efficacy of the OVA-FLs through the skin with or without 
stratum corneum was compared. In this study, no significant 
difference between the anti-OVA IgG levels of the intact 
skin group and the stratum corneum pretreated group was 
observed, which confirmed that the FL system can overcome 
the skin barrier, increase the transcutaneous permeation of 
antigen, and elicit strong immune responses. The underly-
ing mechanism for the efficiency of FLs for transcutaneous 
antigen delivery may be: (1) the encapsulation within such 
particulate delivery systems, which can protect peptides and 
proteins from proteolytic enzymes; (2) the stability of the 
protein, which resulted in the enhanced bioavailability and 
the improved release rate; (3) the sufficiently small size of the 
FL particles (,1 µm), which promoted their passage across 
the skin through skin adhesion and particle internalization; 
(4) or the facilitated presence of antigen to APCs upon the 
enhanced elasticity of FL.
Additionally, it is known that adjuvants used in 
immunology are agents that may stimulate the immune 
system and increase the body response to a vaccine, without 
causing any specific antigenic effects themselves. Currently, 
adjuvants demonstrated with efficacy in immunization can 
be divided into bacterial exotoxins (subunits of the toxins 
are responsible for different cytokine expression from 
restimulated lymphocytes) and Toll-like receptor (TLR) 
ligands (TLRs are important signal molecules when cells 
sense danger).31–33 Langerhans cells express bacteria-sensing 
TLRs, TLR1, TLR2, TLR5, TLR6, and TLR9. In this study, 
imiquimod, a synthetic TLR7 ligand, which belongs to a class 
of immune-response modifiers, was identified as an effective 
adjuvant for transcutaneous immunization and enhanced the 
vaccination effect of OVA-FL vaccine in contrast to that of 
OVA-FLs alone. One of the underlying mechanisms may be 
that imiquimod can activate skin immune cells through TLR7 
and TLR8 and induce the migration of Langerhans cells.34,35
In summary, results gained in the present study indicate 
that FLs can significantly improve the stability, drug entrap-
ment, transcutaneous delivery, and the release of OVA pro-
teins from carriers. FLs were found to be able to increase the 
penetration of protein through stratum corneum and retain it 
in the epidermis and the dermis layers, due to FLs’ flexibility 
and its similar structure to the stratum corneum. In vivo, 
OVA-FLs could enter the skin through skin appendages like 
follicles.36 In the investigation of the immunization effects on 
mice, OVA-FLs exhibited a stronger immunization compared 
with that induced by OVA solution upon transcutaneous 
absorption through intact skin. It was also interesting to find 
that the co-administration of imiquimod can significantly 
increase the IgG levels induced by OVA-FLs. In future, we 
can expect an increasing number of therapeutic molecules 
such as proteins, oligonucleotides, and DNA to be carried 
by nanoscaled carriers as vaccine for immunization and 
gene therapy.
Conclusion
This study has convincingly shown the potential of FLs as a 
promising carrier, as well as the efficiency of the imiquimod 
as a novel adjuvant for transcutaneous antigen delivery, pro-
viding strong evidence for their application in transcutaneous 
immunization. However, in considering the future use of 
FLs for peptide or protein delivery, it is essential that their 
biosafety be studied in more intensive and elaborate trials. 
Particularly, a prospective in vivo tolerance evaluation in 
humans and/or animals should be undertaken.
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